# Vir Biotechnology, Inc. (VIR) · Edgar & Edgarette company card

> Vir Biotechnology (VIR) saw revenue fall 7.6% in FY2025 to $69 million, operating margin -699% against a -15.8% median for biological products, (no diagnostic substances), equity 76.3% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1706431 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/VIR) · [JSON](https://www.pops4.com/boards/company/VIR.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $69M |
| Revenue growth, 1 year | -7.6% |
| Revenue growth per year | -50.0% |
| Operating margin | -699.2% (prior year -791.3%) |
| Net margin | -638.9% |
| Operating cash flow | −$392M |
| Capital spending | $5M |
| Free cash flow | −$397M |
| Cash | $232M |
| Long-term debt | — |
| Total assets | $1.0B |
| Total equity | $765M |
| Equity ÷ assets | 76.3% |
| Return on equity | -57.2% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -0.97 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Health Harbor boat: Rotting at the dock · four or more warning signs · slow and jumpy: growing slower than its size class, with revenue that swings more; operating cash flow was negative; operating loss: a margin of -699.2% in FY2025; revenue is hard to predict: its 80% range is ±46%
- Cash Compass: Fading · slow and jumpy, lagging its peers

## Edgarette's reading

Exposure: revenue $68.6M (FY2025). Experience: revenue down 7.6% on the year, down 50.0% a year over 4 years; operating margin -699.2%, up from -791.3%. Soundness: equity 76.3% of assets, return on equity -57.2%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $25.5M and $69.2M next year (method v4.1: its own 3-year record of growth weighed at 40% against $50M–100M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $26.5M to $66.9M. A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -699.2% against a -15.8% median; growth -7.6% against 21.4%.

Range logged 2026-10-02, receipt 6ae29a608830a0ae, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 7, latest 2026-10-28 ([filing](https://www.sec.gov/Archives/edgar/data/1706431/000162828026067742/0001628280-26-067742-index.htm))

## Recent filings

- 8-K · filed 2026-11-16 · 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1706431/000119312526461412/0001193125-26-461412-index.htm)
- 8-K · filed 2026-11-09 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1706431/000162828026071908/0001628280-26-071908-index.htm)
- 10-Q · filed 2026-11-04 · [filing](https://www.sec.gov/Archives/edgar/data/1706431/000162828026070273/0001628280-26-070273-index.htm)
- 8-K · filed 2026-11-04 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1706431/000162828026070148/0001628280-26-070148-index.htm)
- 8-K · filed 2026-10-28 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/1706431/000162828026067742/0001628280-26-067742-index.htm)
- 8-K · filed 2026-10-14 · 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1706431/000162828026065826/0001628280-26-065826-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001706431.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1706431

## Cite

POPS4, Edgar & Edgarette: Vir Biotechnology, Inc. (VIR) company card, from the company's own SEC filings, accessed 2026-11-16, https://www.pops4.com/boards/company/VIR. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

